Aware Super Pty Ltd as trustee of Aware Super Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR)

Aware Super Pty Ltd as trustee of Aware Super acquired a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 86,680 shares of the biotechnology company's stock, valued at approximately $30,584,000. Aware Super Pty Ltd as trustee of Aware Super owned approximately 0.19% of United Therapeutics at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in UTHR. Newbridge Financial Services Group Inc. purchased a new position in shares of United Therapeutics in the 4th quarter valued at about $25,000. Millstone Evans Group LLC purchased a new position in shares of United Therapeutics during the 4th quarter valued at approximately $67,000. MassMutual Private Wealth & Trust FSB grew its stake in United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock valued at $85,000 after acquiring an additional 58 shares during the period. Jones Financial Companies Lllp increased its holdings in United Therapeutics by 678.9% in the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock worth $104,000 after acquiring an additional 258 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in United Therapeutics during the fourth quarter worth $131,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at United Therapeutics

In related news, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction dated Thursday, April 17th. The shares were sold at an average price of $283.78, for a total value of $3,121,580.00. Following the sale, the executive vice president now directly owns 36,781 shares in the company, valued at approximately $10,437,712.18. The trade was a 23.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $371.05, for a total transaction of $3,710,500.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at approximately $956,195.85. This trade represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 91,500 shares of company stock worth $30,971,540 over the last quarter. 11.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. StockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday. UBS Group raised their target price on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. Finally, HC Wainwright reiterated a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $388.25.

United Therapeutics Price Performance

Shares of UTHR traded down $0.46 during mid-day trading on Friday, reaching $284.73. The stock had a trading volume of 302,945 shares, compared to its average volume of 452,973. United Therapeutics Co. has a 52-week low of $233.28 and a 52-week high of $417.82. The firm has a market cap of $12.79 billion, a price-to-earnings ratio of 12.50, a P/E/G ratio of 0.97 and a beta of 0.63. The business's fifty day moving average is $316.61 and its 200 day moving average is $348.66.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating the consensus estimate of $6.10 by $0.09. The business had revenue of $735.90 million during the quarter, compared to analysts' expectations of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter in the prior year, the company posted $4.36 EPS. As a group, sell-side analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.